Patents by Inventor Yanxin Liu

Yanxin Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Apoptosis-inducing agents
    Patent number: 12312349
    Abstract: Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: May 27, 2025
    Assignees: Fochon Pharmaceuticals, Ltd., Shanghai Fosun Pharmaceutical Industrial Development Co, , Ltd.
    Inventors: Hongbin Liu, Yue Rong, Huajie Zhang, Zhifang Chen, Rui Tan, Chengxi He, Zhifu Li, Zuwen Zhou, Haohan Tan, Kai Ran, Xianlong Wang, Zongyao Zou, Lihua Jiang, Yanxin Liu, Xingdong Zhao, Weibo Wang, Jiemin Fu
  • Method for preparing pharmaceutical composition and pharmaceutical composition
    Patent number: 11723867
    Abstract: The present application relates to a method for preparing a pharmaceutical composition, the method comprising providing pharmaceutical compound having a solubility in water of 1 mg/ml or less at 25° C. in a solvent enabling solubilizing the pharmaceutical compound at least partly into the solvent, providing an aqueous dispersion of nanostructured cellulose, and combining the pharmaceutical compound with the aqueous dispersion of nanostructured cellulose in an anti-solvent process to provide nanosized pharmaceutical particles having an average diameter of 50 nm or less, to provide a pharmaceutical composition. The present application also provides pharmaceutical composition, and use of the pharmaceutical composition.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: August 15, 2023
    Assignee: UPM_KYMMENE CORPORATION
    Inventors: Markus Nuopponen, Huang Xiang, Haiqiu Song, Yulong Wang, Yanxin Liu
  • COMPOUNDS AS PROTEIN KINASE INHIBITORS
    Publication number: 20230174556
    Abstract: Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: May 14, 2021
    Publication date: June 8, 2023
    Inventors: Zuwen ZHOU, Rui TAN, Hua XU, Qihong LIU, Huajie ZHANG, Bin LIU, Weipeng ZHANG, Zhifu LI, Yanxin LIU, Shu LIN, Xingdong ZHAO, Weibo WANG
  • COMPOUNDS USEFUL AS KINASE INHIBITORS
    Publication number: 20230145305
    Abstract: Provided are certain BTK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: March 10, 2021
    Publication date: May 11, 2023
    Inventors: Chengxi HE, Xianlong WANG, Yue RONG, Rui TAN, Huajie ZHANG, Haohan TAN, Yanxin LIU, Shu LIN, Tongshuang LI, Xingdong ZHAO, Weibo WANG
  • Macrocyclic compounds as TRK kinases inhibitors
    Patent number: 11555042
    Abstract: Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: January 17, 2023
    Assignee: Fochon Biosciences, Ltd.
    Inventors: Huajie Zhang, Qihong Liu, Chengxi He, Weipeng Zhang, Rui Tan, Bin Liu, Hong Fu, Haohan Tan, Lijun Yang, Hongbin Liu, Yunling Wang, Yuwei Gao, Zongyao Zou, Yanxin Liu, Shu Lin, Tongshuang Li, Xingdong Zhao, Weibo Wang
  • APOPTOSIS-INDUCING AGENTS
    Publication number: 20220402913
    Abstract: Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: July 15, 2021
    Publication date: December 22, 2022
    Inventors: Hongbin LIU, Yue RONG, Huajie ZHANG, Zhifang CHEN, Rui TAN, Chengxi HE, Zhifu LI, Zuwen ZHOU, Haohan TAN, Kai RAN, Xianlong WANG, Zongyao ZOU, Lihua JIANG, Yanxin LIU, Xingdong ZHAO, Weibo WANG, Jiemin FU
  • SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3,4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
    Publication number: 20220235049
    Abstract: Provided are certain BTK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: June 1, 2020
    Publication date: July 28, 2022
    Inventors: Haohan TAN, Qihong LIU, Bin LIU, Zhifu LI, Xianlong WANG, Zuwen ZHOU, Weipeng ZHANG, Yunling WANG, Chenglin ZHOU, Yuwei GAO, Lihua JIANG, Yanxin LIU, Zongyao ZOU, Shu LIN, Kai YU, Tongshuang LI, Xingdong ZHAO, Weibo WANG
  • SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20220041588
    Abstract: Provided are certain RET inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: September 26, 2019
    Publication date: February 10, 2022
    Inventors: Chengxi HE, Rui TAN, Zuwen ZHOU, Weipeng ZHANG, Yunling WANG, Qihong LIU, Xingdong ZHAO, Yanxin LIU, Yuwei GAO, Shu LIN, Weibo WANG
  • Apoptosis-inducing agents
    Patent number: 11091478
    Abstract: Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: August 17, 2021
    Assignee: Fochon Pharmaceutical Co., Ltd.
    Inventors: Hongbin Liu, Yue Rong, Huajie Zhang, Zhifang Chen, Rui Tan, Chengxi He, Zhifu Li, Zuwen Zhou, Haohan Tan, Kai Ran, Xianlong Wang, Zongyao Zou, Lihua Jiang, Yanxin Liu, Xingdong Zhao, Weibo Wang, Jiemin Fu
  • Compounds as BLC-2-selective apoptosis-inducing agents
    Patent number: 11053239
    Abstract: Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof are provided. In particular, Bcl-2 inhibitors of formula (I) are provided, wherein the variable groups are as defined in the specification. The Bcl-2 inhibitors can be used to treat cell proliferative disorders.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: July 6, 2021
    Assignee: Fochon Pharmaceuticals, Ltd.
    Inventors: Xingdong Zhao, Zuwen Zhou, Chengxi He, Zhifu Li, Yue Rong, Rui Tan, Huajie Zhang, Hongbin Liu, Weipeng Zhang, Haohan Tan, Zhifang Chen, Lihua Jiang, Yanxin Liu, Min Lin, Jing Sun, Weibo Wang
  • MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS
    Publication number: 20210139506
    Abstract: Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: March 27, 2019
    Publication date: May 13, 2021
    Applicants: Fochon Pharmaceuticals, Ltd., Shanghai Fochon Pharmaceutical Co., LTD.
    Inventors: Huajie ZHANG, Qihong LIU, Chengxi HE, Weipeng ZHANG, Rui TAN, Bin LIU, Hong FU, Haohan TAN, Lijun YANG, Hongbin LIU, Yunling WANG, Yuwei GAO, Zongyao ZOU, Yanxin LIU, Shu LIN, Tongshuang LI, Xingdong ZHAO, Weibo WANG
  • Method for preparing pharmaceutical composition and pharmaceutical composition
    Publication number: 20210077403
    Abstract: The present application relates to a method for preparing a pharmaceutical composition, the method comprising providing pharmaceutical compound having a solubility in water of 1 mg/ml or less at 25° C. in a solvent enabling solubilizing the pharmaceutical compound at least partly into the solvent, providing an aqueous dispersion of nanostructured cellulose, and combining the pharmaceutical compound with the aqueous dispersion of nanostructured cellulose in an anti-solvent process to provide nanosized pharmaceutical particles having an average diameter of 50 nm or less, to provide a pharmaceutical composition. The present application also provides pharmaceutical composition, and use of the pharmaceutical composition.
    Type: Application
    Filed: September 9, 2020
    Publication date: March 18, 2021
    Inventors: Markus NUOPPONEN, Huang XIANG, Haiqiu SONG, Yulong WANG, Yanxin LIU
  • Certain protein kinase inhibitors
    Patent number: 10835535
    Abstract: Certain CDK4/6 inhibitors and pharmaceutically acceptable salts thereof are described. In particular, these compounds can inhibit kinase activity of CDK4/6 and may be useful for the treatment of hyper-proliferative diseases like cancer and inflammation. In addition, the pharmaceutical compositions thereof and methods of use thereof are also described.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: November 17, 2020
    Assignees: Shanghai Fochon Pharmaceutical Co., Ltd., Fochon Pharmaceuticals, Ltd.
    Inventors: Xingdong Zhao, Tongshuang Li, Zhifang Chen, Rui Tan, Ling Chen, Xianlong Wang, Lijun Yang, Zuwen Zhou, Yanxin Liu, Min Lin, Jing Sun, Weibo Wang
  • APOPTOSIS-INDUCING AGENTS
    Publication number: 20200115379
    Abstract: Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: April 17, 2018
    Publication date: April 16, 2020
    Inventors: Hongbin LIU, Yue RONG, Huajie ZHANG, Zhifang CHEN, Rui TAN, Chengxi HE, Zhifu LI, Zuwen ZHOU, Haohan TAN, Kai RAN, Xianlong WANG, Zongyao ZOU, Lihua JIANG, Yanxin LIU, Xingdong ZHAO, Weibo WANG, Jiemin FU
  • COMPOUNDS AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS
    Publication number: 20190345156
    Abstract: Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof are provided. In particular, Bcl-2 inhibitors of formula (I) are provided, wherein the variable groups are as defined in the specification. The Bc1-2 inhibitors can be used to treat cell proliferative disorders.
    Type: Application
    Filed: January 5, 2018
    Publication date: November 14, 2019
    Applicants: Shanghai Fochon Pharmaceutical Co., Ltd., Fochon Pharmaceuticals, Ltd.
    Inventors: Xingdong ZHAO, Zuwen ZHOU, Chengxi HE, Zhifu LI, Yue RONG, Rui TAN, Huajie ZHANG, Hongbin LIU, Weipeng ZHANG, Haohan TAN, Zhifang CHEN, Lihua JIANG, Yanxin LIU, Min LIN, Jing SUN, Weibo WANG
  • Certain protein kinase inhibitor
    Patent number: 10450316
    Abstract: Provided are certain CDK4/6 inhibitors with the structure of formula (I), pharmaceutical compositions thereof, and methods of use therefor. The compounds are of the class of pyrimidin-2 amine derivatives, useful for the treatment of hyper-proliferative diseases.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: October 22, 2019
    Assignees: CHONGQING FOCHON PHARMACEUTICAL CO., LTD., SHANGHAI FOCHON PHARMACEUTICAL CO., LTD.
    Inventors: Xingdong Zhao, Tongshuang Li, Haohan Tan, Zhifang Chen, Ling Chen, Qihong Liu, Yue Rong, Lijun Yang, Xianlong Wang, Rui Tan, Zuwen Zhou, Bin Liu, Min Lin, Lihua Jiang, Yanxin Liu, Li Linghu, Jing Sun, Weibo Wang
  • CERTAIN PROTEIN KINASE INHIBITORS
    Publication number: 20190209566
    Abstract: Certain CDK4/6 inhibitors and pharmaceutically acceptable salts thereof are described. In particular, these compounds can inhibit kinase activity of CDK4/6 and may be useful for the treatment of hyper-proliferative diseases like cancer and inflammation. In addition, the pharmaceutical compositions thereof and methods of use thereof are also described.
    Type: Application
    Filed: May 5, 2017
    Publication date: July 11, 2019
    Inventors: Xingdong ZHAO, Tongshuang LI, Zhifang CHEN, Rui TAN, Ling CHEN, Xianlong WANG, Lijun YANG, Zuwen ZHOU, Yanxin LIU, Min LIN, Jing SUN, Weibo WANG
  • Certain protein kinase inhibitors
    Patent number: 10328060
    Abstract: Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use therefor.
    Type: Grant
    Filed: November 1, 2015
    Date of Patent: June 25, 2019
    Assignees: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES, CHONGQING FOCHON PHARMACEUTICAL CO., LTD.
    Inventors: Xingdong Zhao, Jian Ding, Linghua Meng, Meiyu Geng, Tongshuang Li, Zuwen Zhou, Ling Chen, Qihong Liu, Xianlong Wang, Lijun Yang, Yue Rong, Rui Tan, Chuiliang Yu, Lihua Jiang, Yanxin Liu, Li Linghu, Jing Sun, Weibo Wang
  • CERTAIN PROTEIN KINASE INHIBITOR
    Publication number: 20180291027
    Abstract: Provided are certain CDK4/6 inhibitors, pharmaceutical compositions thereof, and methods of use therefor.
    Type: Application
    Filed: April 28, 2016
    Publication date: October 11, 2018
    Inventors: Xingdong ZHAO, Tongshuang LI, Haohan TAN, Zhifang CHEN, Ling CHEN, Qihong LIU, Yue RONG, Lijun YANG, Xianlong WANG, Rui TAN, Zuwen ZHOU, Bin LIU, Min LIN, Lihua JIANG, Yanxin LIU, Li LINGHU, Jing SUN, Weibo WANG
  • Certain protein kinase inhibitors
    Patent number: 10087195
    Abstract: Provided are compound of formula (I) as certain CDK4/6 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: October 2, 2018
    Assignees: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD., CHONGQING FOCHON PHARMACEUTICAL CO., LTD.
    Inventors: Weibo Wang, Xingdong Zhao, Tongshuang Li, Qiang Tian, Huajie Zhang, Haohan Tan, Xianlong Wang, Qihong Liu, Zhifu Li, Weipeng Zhang, Zhifang Chen, Lihua Jiang, Yanxin Liu, Li Linghu, Min Lin, Jing Sun